目的 探讨调血脂药物在武汉市的利用情况与发展趋势.方法 对武汉市34家医院2011—2013年调血脂药物的种类、销售金额和用药频度(DDDs)等进行分析.结果 2011—2013年调血脂药物的年度销售总金额逐年增长,分别为5 900.90、8 129.79、11 000.38万元,其中调血脂药物类别前3名分别为他汀类、中药类和贝特类.各种调血脂药物的DDDs值排序前4名保持不变,且都是他汀类药物,分别是阿托伐他汀钙、辛伐他汀、普伐他汀和氟伐他汀.大部分调血脂药物的B/A值接近1.结论 他汀类药物占武汉市调血脂药物市场中的主导地位,其中阿托伐他汀钙是最常用的品种.

Objective To investigate the current situation and trend of the utilization of lipid-modulating agents (LMAs) in Wuhan City. Methods The utilization data including varieties, consumption sum, and DDDs of LMAs in 34 hospitals in Wuhan City from 2011 to 2013 were analyzed. Results The annual consumption sum of LMAs were 59.009 0, 81.297 9, and 110.003 8 million yuan from 2011 to 2013. The statins, Chinese medicine, and fibrates ranked the top three in LMAs. DDDs of the top four LMAs remained the same. They were all statins, and they respectively were atorvastatin calcium, simvastatin, pravastatin, and fluvastatin. B/A values of most LMAs were almost 1. Conclusion The statins occupy the predominant place among all the LMAs in Wuhan City and atorvastation calcium is the most common species.